2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)

BACKGROUND: DLX is an IV/oral fluoroquinolone with no QT restrictions, and activity against Gram-positive, Gram-negative and atypical pathogens. DLX is approved for treatment of ABSSSI including those due to MRSA and Gram-negative pathogens. A Phase 3 trial of patients with CABP was recently complet...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Autores principales: Salata, Robert, Alvarez-Sala, Rodolfo, Horcajada, Juan P, Lawrence, Laura, Quintas, Megan, Li, Yang, Cammarata, Sue
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810364/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1910
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares